Clinical trials: Tacrolimus
Chronic Myeloproliferative Disorders, Leukemia
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00104975
- Testing
- alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
End-stage Renal Failure
The ONE Study UK Treg Trial
A study to assess cell therapy as a treatment to prevent kidney transplant rejection. The trial will involve purification of naturally occurring regulatory T cells (nTregs) from living-donor renal transplant recipients.
- Trial name
- ONETreg1 (NCT02129881)
- Testing
- Autologous regulatory T Cell Product
- Where
- 2 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Kidney Transplantation
Iguratimod in Kidney Transplant Recipients
The objective of the study is to evaluate the effect of iguratimod concomitant with conventional immunosuppressive drugs on preventing antibody-induced rejection in HLA Highly mismatched Kidney Transplant recipients.
- Trial name
- NCT02839941
- Testing
- Iguratimod, Mycophenolate mofetil, Tacrolimus
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Ocular Graft-versus-host Disease
Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT
Chronic GVHD (cGVHD) is a predominant cause of mortality and disability not related to relapse; it occurs in 30 to 70% of patients.
- Trial name
- NCT06348602
- Testing
- Cyclosporine ophthalmic solution 0.1%, Tacrolimus ophthalmic ointment 0.03%
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Leukemia, Lymphoma
Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00004145
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Pediatric Liver Transplantation
Prospective Tacrolimus Pharmacokinetics Study in Pediatric Living Donor Liver Transplantation
Our first aim is thus to investigate, retrospectively first and then prospectively, in de novo pediatric (living donor) liver recipients, the tacrolimus in vivo and in vitro metabolism and its variability with focus on…
- Trial name
- NCT02064777
- Testing
- Tacrolimus
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Kidney Transplantation
Genetic Factors on Outcomes of Kidney Transplant Patients With Tacrolimus-based Therapy
The purpose of this study is to identify the influence of genetic and clinical factors on the clinical outcomes of kidney transplant patients with tacrolimus (TAC) based immunosuppression in Taiwan.
- Trial name
- NCT03764670
- Where
- Taiwan
- Volunteers
- 98 people
- Sponsor
- National Taiwan University Hospital
DiGeorge Anomaly, Complete DiGeorge Anomaly
Phase I/II Thymus Transplantation With Immunosuppression #950
The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and…
- Conditions
- DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- #950 (NCT00579527)
- Testing
- Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Liver Transplantation
A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients
A study to assess the pharmacokinetics, safety and effectiveness of tacrolimus in stable pediatric liver transplant patients converted from a Prograf® based immunosuppression regimen to a modified release tacrolimus based…
- Trial name
- NCT00282256
- Testing
- tacrolimus modified release (MR), tacrolimus
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Astellas Pharma Inc
Leukemia, Lymphoma
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a complication of transplantation where the donor graft attacks and damages some of your tissues.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndrome
- Trial name
- NCT01323920
- Testing
- Bortezomib, Tacrolimus, Methotrexate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dana-Farber Cancer Institute
Dermatitis, Atopic
Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment
A long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis, and…
- Trial name
- NCT00480896
- Testing
- tacrolimus ointment
- Where
- 22 sites in Belgium, Czechia and 9 more
- Volunteers
- 250 people
- Sponsor
- Astellas Pharma Inc
Kidney Cancer
Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer
RATIONALE: A peripheral stem cell transplant or bone marrow transplant from a brother or sister may be an effective treatment for kidney cancer.
- Trial name
- NCT00262886
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Rochester
Skin Neoplasms, Kidney Transplantation
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.
- Trial name
- NCT00129961
- Testing
- sirolimus, cyclosporine or tacrolimus
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 86 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hematologic Neoplasms
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
This is a pilot study to evaluate the feasibility, safety and potential benefits of removing one immune suppressive drug called mycophenolate mofetil (MMF) from the standard allogenic stem cell transplant treatment protocol.
- Trial name
- OmitMMF (NCT05256537)
- Testing
- Omission of the drug mycophenolate mofetil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ronald Paquette
Hematopoietic and Lymphoid System Neoplasm
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of bendamustine when given with or without cyclophosphamide in preventing graft versus host disease (GVHD) in patients undergoing stem cell transplant.
- Trial name
- NCT04022239
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Bendamustine, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Vitiligo
T Central Memory Cells in Early Localized Non-Segmental Vitiligo
Assessing the level of circulating TCMs (cluster of differentiation (CD) 8+, CD3+,C- chemokine receptor (CCR)7, cluster of differentiation 45 receptor (CD45R) cells) in early localized vitiligo cases prior to treatment and after…
- Trial name
- NCT05706636
- Testing
- oral mini pulse, Topical cream, targeted phototherapy
- Where
- Egypt
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Cairo University
Transplant Recipient (Kidney)
Immune Monitoring-Guided Individualized Tacrolimus Therapy in Renal Transplant Recipients: An Observational Study and PK/PD Modeling
This study aims to resolve the clinical limitation that therapeutic drug monitoring (TDM) alone cannot accurately reflect the net immune status after kidney transplantation.
- Trial name
- NCT07815938
- Testing
- No interventional treatment, only observational data collection without clinical drug adjustment
- Volunteers
- 50 people
- Sponsor
- Zhongnan Hospital
Kidney Transplant; Complications
Once Daily Immunosuppression Regimen
The purpose of this research study is to determine whether an immunosuppressive maintenance regimen of Envarsus/azathioprine compared to a tacrolimus/ mycophenolic acid regimen is associated with better compliance, tolerability…
- Trial name
- NCT03555448
- Testing
- Once daily immunosuppression regimen, Twice daily immunosuppression regimen
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Washington University School of Medicine
Liver Transplant
EVR and EPO for Liver Transplant Tolerance
This is an open label, single-arm, multicenter phase 1b study of stable adult liver transplant recipients on a tacrolimus (TAC)-based immunosuppression (IS) regimen who will transition from TAC to Everolimus (EVR), receive five…
- Trial name
- EVEREST (NCT06832189)
- Testing
- Everolimus, Epoetin alfa
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplantation, Kidney Transplantation
Impact of P-gp, MRP2, ENT-1 and CNT3 on the Blood Concentration / Intra-PBMC Concentration of Tacrolimus
Prospective and monocentric pharmacokinetic study
- Trial name
- TRANS-TAC (NCT03910868)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Rennes University Hospital